

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bolzon Bradley J PhD</u>  (Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC. 139 MAIN STREET  (Street) CAMBRIDGE MA 02142  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Black Diamond Therapeutics, Inc. [ BDTX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 07/27/2020	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person  <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/27/2020		j <sup>(1)</sup>		192,576	D	\$0.00	2,017,016	I	See Footnote <sup>(2)</sup>
Common Stock	07/27/2020		j <sup>(3)</sup>		1,033	A	\$0.00	1,033	I	See Footnote <sup>(4)</sup>
Common Stock	07/27/2020		j <sup>(5)</sup>		57,424	D	\$0.00	601,445	I	See Footnote <sup>(6)</sup>
Common Stock	07/27/2020		j <sup>(7)</sup>		3,098	A	\$0.00	4,131	I	See Footnote <sup>(4)</sup>
Common Stock	07/27/2020		j <sup>(8)</sup>		4,131	D	\$0.00	0	I	See Footnote <sup>(4)</sup>
Common Stock	07/27/2020		j <sup>(8)</sup>		1,449	A	\$0.00	1,449	D	
Common Stock	07/27/2020		j <sup>(9)</sup>		79,217	D	\$0.00	1,127,386	I	See Footnote <sup>(10)</sup>
Common Stock	07/27/2020		j <sup>(11)</sup>		1,187	A	\$0.00	1,187	I	See Footnote <sup>(12)</sup>
Common Stock	07/27/2020		j <sup>(13)</sup>		1,187	D	\$0.00	0	I	See Footnote <sup>(12)</sup>
Common Stock	07/27/2020		j <sup>(14)</sup>		1,177	A	\$0.00	1,177	I	See Footnote <sup>(15)</sup>
Common Stock	07/27/2020		j <sup>(16)</sup>		1,177	D	\$0.00	0	I	See Footnote <sup>(15)</sup>
Common Stock	07/27/2020		j <sup>(16)</sup>		42	A	\$0.00	1,491	D	
Common Stock								6,809,414	I	See Footnote <sup>(17)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Date Exercisable	Expiration Date					

**Explanation of Responses:**

- Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I, L.P. ("Versant Voyageurs I"), to its partners, pursuant to a Rule 10b5-1 distribution plan.
- Shares held by Versant Voyageurs I. Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I. The Reporting Person, a member of the Issuer's board

- of directors, may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
3. Represents a change in the form of ownership of Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP LP") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Voyageurs I.
4. Shares held by Versant Voyageurs I GP LP. The Reporting Person, a member of the Issuer's board of directors, is a partner of Versant Voyageurs I GP LP and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
5. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), to its partners, pursuant to a Rule 10b5-1 distribution plan.
6. Shares held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
7. Represents a change in the form of ownership of Versant Voyageurs I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant I Parallel.
8. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Voyageurs I GP LP, to its partners, pursuant to a Rule 10b5-1 distribution plan.
9. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("Versant Vantage I"), to its partners, pursuant to a Rule 10b5-1 distribution plan.
10. Shares held by Versant Vantage I. Versant Vantage I GP, L.P. ("Versant Vantage I GP LP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP LP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
11. Represents a change in the form of ownership of Versant Vantage I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I.
12. Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
13. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP LP, to its partners, pursuant to a Rule 10b5-1 distribution plan.
14. Represents a change in the form of ownership of Versant Vantage I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP LP.
15. Shares held by Versant Vantage I GP-GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
16. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP-GP, to its members, pursuant to a Rule 10b5-1 distribution plan.
17. Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP is the general partner of Versant VI, and Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. The Reporting Person, a member of the Issuer's board of directors, is a managing member of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

**Remarks:**

/s/ Robin L. Praeger, Attorney  
- in -fact for Bradley J. Bolzon, PhD.      07/29/2020

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**